drugset / Trial / NCT00002110

A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

NCT00002110 ↗

Phase 2 Completed 300 enrolled Mylan Laboratories
Double-blindTreatment

Summary

To determine the safety and tolerance of low-dose versus high-dose cysteamine administered concurrently with zidovudine (AZT). To determine the pharmacokinetics and effects on immune function and viral load in patients receiving these drug regimens.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cysteamine Unknown — —
Background Zidovudine Small molecule — —